These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 35935930)

  • 21. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
    Tahmasebi S; Elahi R; Esmaeilzadeh A
    Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bright future or blind alley? CAR-T cell therapy for solid tumors.
    Zhang K; Chen H; Li F; Huang S; Chen F; Li Y
    Front Immunol; 2023; 14():1045024. PubMed ID: 36761757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
    Miao L; Zhang Z; Ren Z; Tang F; Li Y
    Front Immunol; 2021; 12():687822. PubMed ID: 34093592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
    Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
    Front Immunol; 2022; 13():871661. PubMed ID: 35911706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric Antigen Receptor (CAR) T-cell Therapy: A New Genetically Engineered Method of Immunotherapy for Cancer.
    Singh AK; Malviya R; Singh A; Sundram S; Mishra S
    Curr Cancer Drug Targets; 2023; 23(3):199-210. PubMed ID: 36173082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-throughput method to analyze the cytotoxicity of CAR-T Cells in a 3D tumor spheroid model using image cytometry.
    Zurowski D; Patel S; Hui D; Ka M; Hernandez C; Love AC; Lin B; Moore A; Chan LL
    SLAS Discov; 2023 Apr; 28(3):65-72. PubMed ID: 36758833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
    Qian L; Chen J; Wu X; Jing R; Sun J
    Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.
    Noraldeen SAM; Rasulova I; Lalitha R; Hussin F; Alsaab HO; Alawadi AH; Alsaalamy A; Sayyid NH; Alkhafaji AT; Mustafa YF; Shayan SK
    Med Oncol; 2023 Oct; 40(11):313. PubMed ID: 37779152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Theranostic chimeric antigen receptor (CAR)-T cells: Insight into recent trends and challenges in solid tumors.
    Kheyrolahzadeh K; Tohidkia MR; Tarighatnia A; Shahabi P; Nader ND; Aghanejad A
    Life Sci; 2023 Sep; 328():121917. PubMed ID: 37422069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
    Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
    Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
    Huang J; Huang X; Huang J
    Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hurdles to breakthrough in CAR T cell therapy of solid tumors.
    Marofi F; Achmad H; Bokov D; Abdelbasset WK; Alsadoon Z; Chupradit S; Suksatan W; Shariatzadeh S; Hasanpoor Z; Yazdanifar M; Shomali N; Khiavi FM
    Stem Cell Res Ther; 2022 Apr; 13(1):140. PubMed ID: 35365241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors.
    Adachi K; Tamada K
    Cancer Sci; 2022 Dec; 113(12):4020-4029. PubMed ID: 36047968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer.
    Yin L; Chen GL; Xiang Z; Liu YL; Li XY; Bi JW; Wang Q
    Biomed Pharmacother; 2023 Jun; 162():114648. PubMed ID: 37023621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Making CAR T Cells a Solid Option for Solid Tumors.
    Schmidts A; Maus MV
    Front Immunol; 2018; 9():2593. PubMed ID: 30467505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
    Yu T; Yu SK; Xiang Y; Lu KH; Sun M
    Front Immunol; 2022; 13():936496. PubMed ID: 35903099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy.
    Liu Z; Zhou Z; Dang Q; Xu H; Lv J; Li H; Han X
    Theranostics; 2022; 12(14):6273-6290. PubMed ID: 36168626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric Antigen Receptors for the Tumour Microenvironment.
    Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
    Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.